Compare PAR & MRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PAR | MRVI |
|---|---|---|
| Founded | 1968 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Office Equipment/Supplies/Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 640.6M | 559.0M |
| IPO Year | 1995 | 2020 |
| Metric | PAR | MRVI |
|---|---|---|
| Price | $13.46 | $5.02 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 4 |
| Target Price | ★ $33.20 | $4.13 |
| AVG Volume (30 Days) | 1.5M | ★ 3.1M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 14.29 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $455,547,000.00 | $185,743,000.00 |
| Revenue This Year | $9.82 | $12.54 |
| Revenue Next Year | $11.27 | $7.87 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 30.16 | N/A |
| 52 Week Low | $11.59 | $1.99 |
| 52 Week High | $72.15 | $5.21 |
| Indicator | PAR | MRVI |
|---|---|---|
| Relative Strength Index (RSI) | 41.80 | 68.65 |
| Support Level | $12.32 | $3.27 |
| Resistance Level | $15.10 | $5.00 |
| Average True Range (ATR) | 0.95 | 0.24 |
| MACD | -0.12 | 0.02 |
| Stochastic Oscillator | 3.44 | 78.51 |
PAR Technology Corp is a foodservice technology company providing omnichannel cloud-based software and hardware solutions to the restaurant industry in three restaurant categories - quick service, fast casual, and table service - and the retail industry, including convenience and fuel retailers (C-Stores). Its product and service offerings include point-of-sale, customer engagement and loyalty, digital ordering and delivery, operational intelligence, payment processing, hardware, and related technologies, solutions, and services. The company generates revenue from subscription service, Sale of Hardware products, and Professional Service.
Maravai LifeSciences Holdings Inc is a life sciences company providing products and services to enable the development of drugs, therapeutics, vaccines and diagnostics, and to support research on human disease. Its product portfolio includes complex nucleic acids, custom enzymes and antibody-based solutions for therapeutic, vaccine, diagnostic and biopharmaceutical production applications. The Company operates through two segments: TriLink, which generates maximum revenue from North America and provides nucleic acid products and services including mRNA, oligonucleotides and related technologies; and Cygnus, which provides biologics safety testing products and services including host cell protein ELISA kits, impurity detection assays and related reagents and services.